Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleylacetoacetate SCHEMBL380205 | 1.00 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| Maleylacetoacetate SCHEMBL187863 | 1.00 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL2780998 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL2780997 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL1225122 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL12568561 | 0.84 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| SCHEMBL6916408 | 0.78 | LDHA (0.36) | TSHREGLN1LDHASRRKDM4E | |
| Maleic Acid SCHEMBL1038087 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL28422912 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL1038089 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119403569-A | Systems and methods for treating disorders and diseases using alternating electric fields and CRISPR-Cas systems | 诺沃库勒有限责任公司 | 2025-02-07 | — | — | CN | claimed |
| CN-118451179-A | Gene therapy for the treatment of HT1 | 逻辑生物治疗公司 | 2024-08-06 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-114729100-A | Blocked polyisocyanate crosslinkers, process for their preparation and coating compositions comprising the crosslinkers | 巴斯夫涂料有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20190285632-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-09-19 | — | — | US | claimed |
| EP-3510148-A1 | HIV CLINICAL PLAN | Excision Biotherapeutics, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190194652-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | claimed |
| EP-3465213-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | Excision Biotherapeutics, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2018049372-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS INC (US) | 2018-03-15 | — | — | WO | claimed |
| WO-2017205460-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| CN-119876337-A | High-throughput screening method of 2-keto-3-deoxy-D-xylonate dehydratase mutant library and application of mutant in biosynthesis of alpha-ketoglutarate | 青岛农业大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119746104-A | Tissue-targeting aerosol inhalation type lipid nanoparticle and delivery method and application thereof | 中国科学院动物研究所 | 2025-04-04 | — | — | CN | disclosed |
| US-20030157082-A1 | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003065006-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20010005749-A1 | Aromatic amino acid catabolism enzymes | CAHOON EDGAR B (US) | 2001-06-28 | — | — | US | disclosed |
| US-6218169-B1 | SUCH AS HOMOGENTISATE 1,2-DIOXYGENASE OR A FUMARYLACETOACETASE, WHICH ARE PART OF THE PHENYLALANINE/TYROSINE DEGRADATION CYCLE, ENCODED BY NUCLEIC ACIDS; CHIMERIC GENE; TRANSFORMED HOST CELL | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-04-17 | — | — | US | disclosed |
| CN-1226932-A | Process for inactivation of genes which code for enzymes for catabolism of phenyl acetate, plasmids involved in such process and strains transformed therewith | ANTIBIOTICOS SA (ES) | 1999-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | TSHR 470/4885TP53 3227/4885EGLN1 1832/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | TSHR 1704/4885TP53 2128/4885EGLN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.